GeneDx Holdings (WGS) Misses Q2 EPS by 46c; offers guidance

GeneDx Holdings (NASDAQ: WGS) reported Q2 EPS of ($1.10), $0.46 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $70.51 million versus the consensus estimate of $59.8 million.

GUIDANCE

GeneDx Holdings sees full year 2024 revenues1 between $255 and $265 million versus the consensus of $242.4 million.

For earnings history and earnings-related data on GeneDx Holdings (WGS) click here.

You May Also Be Interested In

• Notice to Long-Term Shareholders of Badger Meter, Inc. (NYSE: BMI); GeneDx Holdings Corp. (NASDAQ: WGS); GRAIL, Inc. (NASDAQ: GRAL); and Verra Mobility Corporation (NASDAQ: VRRM): Grabar Law Office i
• SPS Commerce hires Morgan Stanley, explores sale - Reuters
• Varonis Said To Weigh Sale After Takeover Interest - Bloomberg